Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

Am J Ther. 2022 Sep-Oct;29(5):e572-e575. doi: 10.1097/MJT.0000000000001503.

Alberto Cordero^{1

2}, Julio Nuñez^{2

3}, Vicente Bertomeu-González^{1

2}, Lorenzo Fácila⁴, Mª Amparo Quintanilla¹, Moisés Rodríguez-Mañero^{2

5}, David Escribano¹, Alfonso Valle⁶, Rafael de la Espriella^{2

3}, Javier Torres-Llergo⁷, Antoni Bayés-Genís^{2

8}, José R González-Juanatey^{2

5}

¹ Cardiology Department, Hospital Universitario de San Juan, Alicante, Spain.
² Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain.
³ Cardiology Department, Hospital Clínico Universitario, Valencia, Spain.
⁴ Cardiology Department, Hospital General Universitario de Valencia, Valencia, Spain.
⁵ Cardiology Department, Complejo Hospital Universitario de Santiago, Santiago de Compostela, Spain.
⁶ Cardiology Department, Hospital de Denia, Denia, Spain.
⁷ Cardiology Department, Hospital Universitario de Jaen, Jaen, Spain.
⁸ Cardiology Department, Hospital Germans Trias y Pujol, Badalona, Spain.

No abstract available

Publication types